ITA7089
ITA7089
ITA7089
from
$526.00
Price in reward points: 526
- Catalog: ITA7089
- Gene/Protein: GZMB
- Product Description: Immunotag™ GZMB Antibody
Available Options
-
Description
Immunotag™ GZMB Antibody
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein GZMB Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,ELISA Recommended Dilution WB 1:500-1:2000 IHC 1:50-1:200 Concentration 1 mg/ml Reactive Species Human Host Species Rabbit Immunogen A synthesized peptide derived from human GZMB Specificity GZMB Antibody detects endogenous levels of total GZMB Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name GZMB Accession No. P10144 Alternate Names C11; Cathepsin G like 1; Cathepsin G-like 1; CCPI; CGL 1; CGL1; CSP B; CSPB; CTLA-1; CTLA1; CTSGL1; Cytotoxic serine protease B; Cytotoxic T lymphocyte associated serine esterase 1; Cytotoxic T lymphocyte proteinase 2; Cytotoxic T-lymphocyte proteinase 2; Fragmentin 2; Fragmentin-2; GRAB_HUMAN; Granzyme 2; Granzyme B (granzyme 2, cytotoxic T lymphocyte associated serine esterase 1); Granzyme B; Granzyme-2; GranzymeB; GRB; Gzmb; Hlp; Human lymphocyte protein; Lymphocyte protease; Protease, serine, B; SECT; T cell serine protease 1-3E; T-cell serine protease 1-3E; Description This enzyme is necessary for target cell lysis in cell-mediated immune responses. It cleaves after Asp. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -7, -9 and 10 to give rise to active enzymes mediating apoptosis. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 27kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | GZMB |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,ELISA |
| Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human GZMB |
| Specificity | GZMB Antibody detects endogenous levels of total GZMB |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | GZMB |
| Accession No. | P10144 |
| Alternate Names | C11; Cathepsin G like 1; Cathepsin G-like 1; CCPI; CGL 1; CGL1; CSP B; CSPB; CTLA-1; CTLA1; CTSGL1; Cytotoxic serine protease B; Cytotoxic T lymphocyte associated serine esterase 1; Cytotoxic T lymphocyte proteinase 2; Cytotoxic T-lymphocyte proteinase 2; Fragmentin 2; Fragmentin-2; GRAB_HUMAN; Granzyme 2; Granzyme B (granzyme 2, cytotoxic T lymphocyte associated serine esterase 1); Granzyme B; Granzyme-2; GranzymeB; GRB; Gzmb; Hlp; Human lymphocyte protein; Lymphocyte protease; Protease, serine, B; SECT; T cell serine protease 1-3E; T-cell serine protease 1-3E; |
| Description | This enzyme is necessary for target cell lysis in cell-mediated immune responses. It cleaves after Asp. Seems to be linked to an activation cascade of caspases (aspartate-specific cysteine proteases) responsible for apoptosis execution. Cleaves caspase-3, -7, -9 and 10 to give rise to active enzymes mediating apoptosis. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 27kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |